Enasidenib monotherapy is effective and well-tolerated in patients with previously untreated mutant-IDH2 (m IDH2) acute myeloid leukemia (AML) Meeting Abstract

  

Authors:	Pollyea, D. A.; Tallman, M. S.; De Botton, S.; DiNardo, C. D.; Kantarjian, H. M.; Collins, R. H.; Stein, A. S.; Xu, Q.; Tosolini, A.; Gupta, I.; Agresta, S. V.; Stein, E. M.
Abstract Title:	Enasidenib monotherapy is effective and well-tolerated in patients with previously untreated mutant-IDH2 (m IDH2) acute myeloid leukemia (AML)
Meeting Title:	59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	130
Issue:	Suppl. 1
Meeting Dates:	2017 Dec 9-12
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2017-12-07
Language:	English
ACCESSION:	WOS:000432419401285
PROVIDER:	wos
DOI:	10.1182/blood.V130.Suppl_1.638.638
Notes:	Meeting Abstract: 638 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/127126